Clinically, Gas6 expression in tumor specimens has been identified as an adverse prognostic factor for several cancer types, including urothelial, ovarian, lung adenocarcinoma, gastric cancer, and glioblastoma 32. This evidence concerns the gene GAS6 and lung adenocarcinoma.